Featured Content Delcath Systems, Inc. (DCTH) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. Founded in 1988, Delcath specializes in regional chemotherapy systems that deliver high doses of chemotherapy directly to tumors while minimizing systemic exposure and side effects. The company’s flagship product, the Delcath Hepatic Delivery […]
Read MoreFeatured Content TG Therapeutics, Inc. (TGTX) is a biotechnology company focused on developing innovative therapies for the treatment of B-cell diseases, including various forms of cancer and autoimmune disorders. Founded in 2012, the company is committed to advancing the treatment landscape through the development of novel, targeted therapies that aim to improve patient outcomes. TG […]
Read MoreFeatured Content Alpha Teknova, Inc. is a biotechnology company that specializes in producing and supplying critical reagents, media, and buffers used in life sciences research, diagnostics, and biopharmaceutical production. Headquartered in Hollister, California, Teknova serves a wide range of customers in industries such as gene therapy, cell therapy, and vaccine development. The company’s products are […]
Read MoreQ32 Bio Inc. is a biotechnology company focused on developing therapies to treat severe autoimmune and inflammatory diseases. The company leverages its deep understanding of immune system biology to develop novel treatments that address the root causes of these debilitating conditions. Q32 Bio’s pipeline includes both antibody-based therapies and targeted cytokine inhibitors aimed at regulating […]
Read MoreDyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases. The company’s proprietary FORCE™ platform is designed to deliver targeted therapies to muscle tissue, addressing the underlying genetic causes of debilitating diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular […]
Read MoreCorbus Pharmaceuticals Holdings, Inc. (CRBP) is a biopharmaceutical company focused on developing innovative therapies to address rare, chronic, and serious inflammatory and fibrotic diseases. Their main objective is to improve the lives of patients suffering from these debilitating conditions. The company’s key product, lenabasum, is an investigational drug designed to modulate the immune response, reducing […]
Read MoreDianthus Therapeutics, Inc. (DNTH) Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. Soleno Therapeutics, Inc. (SLNO) Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Super Micro Computer, Inc. (SMCI) Super Micro Computer, Inc., together […]
Read MoreDyne Therapeutics, Inc. is a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases. The company utilizes its proprietary FORCE™ platform to deliver targeted therapies that address the underlying genetic causes of muscle disorders. Dyne Therapeutics’ pipeline includes treatments for diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 […]
Read MoreTaysha Gene Therapies, Inc. (TSHA) is a biotechnology company dedicated to developing and commercializing gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS). The company focuses on using adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target cells, aiming to address the root causes of these diseases. […]
Read MoreNeurogene Inc. (NGNE) is a biotechnology company dedicated to developing life-changing genetic therapies for patients suffering from rare neurological diseases. Their primary focus is on creating innovative treatments that address the root causes of these disorders at the genetic level. Neurogene’s key product candidates include gene therapy programs aimed at conditions such as Batten disease […]
Read MoreStoke Therapeutics, Inc. (STOK) is a biotechnology company focused on developing innovative treatments for genetic diseases. Their primary aim is to address severe genetic disorders by upregulating protein expression using their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform allows Stoke to precisely increase the production of proteins that are deficient due […]
Read MoreHeron Therapeutics is a biotechnology company that focuses on developing and commercializing treatments to address unmet medical needs, particularly in the areas of pain management and oncology. The company leverages its proprietary Biochronomer drug delivery technology to create innovative therapies that can improve patient outcomes and quality of life.One of Heron Therapeutics’ key products is […]
Read MoreJanux Therapeutics Inc. JANX is a biotechnology company specializing in the development of novel cancer immunotherapies designed to enhance the body’s ability to harness the immune system to combat cancer. The company focuses on creating therapies that are not only effective but also have reduced side effects, improving patient outcomes in the fight against cancer. […]
Read MoreADC Therapeutics focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of […]
Read MoreJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique […]
Read More